Episurf Medical AB Series B
Episurf Medical AB (publ), a medical device company, designs and manufactures implants and surgical instruments in Germany, Sweden, rest of Europe, the United States, and internationally. It offers Episealer Knee for repairing focal cartilage and bone defects to reduce pain and increase mobility in the patient's knee joint; Episealer implant, which is designed to fit anatomy and size of the lesio… Read more
Episurf Medical AB Series B (0QUT) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2021: -0.118x
Based on the latest financial reports, Episurf Medical AB Series B (0QUT) has a cash flow conversion efficiency ratio of -0.118x as of September 2021.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-14.30 Million) by net assets (Skr120.80 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Episurf Medical AB Series B - Cash Flow Conversion Efficiency Trend (2018–2020)
This chart illustrates how Episurf Medical AB Series B's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Episurf Medical AB Series B Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Episurf Medical AB Series B ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
CYVIZ AS NK 110
F:8P9
|
N/A |
|
Zhibao Technology Inc. Class A Ordinary Shares
NASDAQ:ZBAO
|
-3.826x |
|
Japan Real Estate Investment Corporation
F:JUA
|
N/A |
|
Helium Evolution Incorporated
PINK:HEEVF
|
-0.013x |
|
Europen Endustri Insaat Sanayi ve Ticaret A.S.
IS:EUREN
|
0.005x |
|
ALDER RESOURCES VTG
F:2JA
|
N/A |
|
IL&FS Engineering and Construction Company Limited
NSE:IL&FSENGG
|
0.015x |
|
Widodo Makmur Perkasa PT
JK:WMPP
|
-0.003x |
Annual Cash Flow Conversion Efficiency for Episurf Medical AB Series B (2018–2020)
The table below shows the annual cash flow conversion efficiency of Episurf Medical AB Series B from 2018 to 2020.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2020-12-31 | Skr169.50 Million | Skr-54.10 Million | -0.319x | +77.68% |
| 2019-12-31 | Skr41.40 Million | Skr-59.20 Million | -1.430x | -22.49% |
| 2018-12-31 | Skr44.80 Million | Skr-52.30 Million | -1.167x | -- |